• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组人干扰素α-2C用于化疗难治性恶性肿瘤患者的I期研究。

Phase I study of recombinant human interferon alpha-2C in patients with chemotherapy-refractory malignancies.

作者信息

Janssen J T, Ludwig H, Scheithauer W, de Pauw B E, Keyser A, van Tol R, Flener R

出版信息

Oncology. 1985;42 Suppl 1:3-6. doi: 10.1159/000226075.

DOI:10.1159/000226075
PMID:4080299
Abstract

Twenty-two patients with advanced haemopoietic and other malignancies were treated intramuscularly with recombinant interferon-alpha 2C in a daily escalating dose. The most common side-effects were flu-like symptoms. Two patients showed severe neurotoxicity, which was completely reversible in 1 case. Doses above 30 X 10(6) IU/day were poorly tolerated and could only be achieved in a minority of the patients. Objective tumour responses were documented in malignant lymphomas, hairy cell leukaemia, and renal cell carcinoma.

摘要

22例晚期造血系统恶性肿瘤及其他恶性肿瘤患者接受了重组干扰素α-2C肌肉注射治疗,剂量每日递增。最常见的副作用是流感样症状。2例患者出现严重神经毒性,其中1例完全可逆。每日剂量超过30×10⁶IU时耐受性较差,只有少数患者能够达到该剂量。在恶性淋巴瘤、毛细胞白血病和肾细胞癌中记录到了客观的肿瘤反应。

相似文献

1
Phase I study of recombinant human interferon alpha-2C in patients with chemotherapy-refractory malignancies.重组人干扰素α-2C用于化疗难治性恶性肿瘤患者的I期研究。
Oncology. 1985;42 Suppl 1:3-6. doi: 10.1159/000226075.
2
Interferon-alpha-2C in the treatment of advanced hairy cell leukaemia. Results of a phase II trial.α-2C干扰素治疗晚期毛细胞白血病。一项II期试验的结果。
Oncology. 1985;42 Suppl 1:7-9. doi: 10.1159/000226076.
3
Phase I study of recombinant human interferon beta in patients with advanced cancer.重组人干扰素β用于晚期癌症患者的I期研究。
J Biol Response Mod. 1987 Apr;6(2):121-9.
4
[Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].[干扰素(IFN)疗法(重组干扰素α-2C或重组干扰素γ)治疗转移性肾细胞癌]
Acta Med Austriaca. 1985;12(5):129-34.
5
Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma.重组干扰素的II期试验结果:肾细胞癌和恶性黑色素瘤
Oncology. 1985;42 Suppl 1:26-32. doi: 10.1159/000226081.
6
Clinical studies of recombinant interferon alfa-2a (Roferon-A) in cancer patients.重组干扰素α-2a(罗扰素-A)在癌症患者中的临床研究。
Cancer. 1986 Apr 15;57(8 Suppl):1705-8. doi: 10.1002/1097-0142(19860415)57:8+<1705::aid-cncr2820571314>3.0.co;2-u.
7
[Results of a multicenter study of the efficacy of recombinant alpha-2c interferon in hairy cell leukemia].[重组α-2c干扰素治疗毛细胞白血病多中心疗效研究结果]
Ned Tijdschr Geneeskd. 1987 Nov 14;131(46):2081-5.
8
Phase I study of recombinant beta ser 17 interferon in the treatment of cancer.
Cancer Treat Rep. 1986 Dec;70(12):1365-72.
9
[Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
Acta Med Austriaca. 1985;12(5):115-21.
10
Phase I study of human leukocyte interferon in patients with advanced cancer.人白细胞干扰素用于晚期癌症患者的I期研究。
J Biol Response Mod. 1983;2(1):47-56.

引用本文的文献

1
Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.干扰素-α可纠正骨髓增殖性疾病患者的血小板增多症。
Cancer Immunol Immunother. 1987;25(3):266-73. doi: 10.1007/BF00199157.